Charter of the Pediatric Advisory Committee to the Food and Drug Administration
Authority
The Pediatric Advisory Committee was established under 15 U.S.C. 1451 et seq.; 21 U.S.C. 321, 341, 342, 343, 343-1,344, 345, 346, 348, 349, 350, 350a, 351, 352, 353(f), 355, 360b, 360c-j, 371, 375, 376, 378, 379e, 381, 393, 394, 881(b); 42U.S.C.217a, 241, 242, 242a, 262, 264; 284m, 289, 290b; Public Law 107-109, Best Pharmaceuticals for Children Act; Public Law 108-155, Pediatric Research Equity Act of 2003; Public Law 110-85, the Food and Drug Administration Amendments Act of 2007; Public Law 112-144, the Food and Drug Administration Safety and Innovation Act of 2012; 21 CFR Part 14, 330.10(a); H.R.307, Pandemic and All-Hazards Preparedness Reauthorization Act of 2013; Pub. L. 92-463, the Federal Advisory Committee Act, as amended (5 U.S.C. App).
Objectives and Scope of Activities
The Pediatric Advisory Committee advises and makes recommendations to the Commissioner or designee in discharging responsibilities as they relate to matters in pediatric therapeutics (including drugs and biological products) and medical devices, pediatric research, pediatric ethical issues and other matters involving pediatrics for which the Food and Drug Administration has regulatory responsibility. The Committee also advises and makes recommendations to the Secretary pursuant to 45 CFR 46.407 on research involving children as subjects that is conducted or supported by the Department of Health and Human Services.
Description of Duties
The Committee reviews and evaluates and makes recommendations to the Commissioner of Food and Drugs regarding (1) pediatric research conducted under sections 351, 409I, and 499 of the Public Health Service Act and sections 501,502, 505, 505A, and 505B, 510K, 515, and 520m of the Federal Food, Drug, and Cosmetic Act; (2) identification of research priorities related to pediatric therapeutics (including drugs and biological products) and medical devices for pediatric populations and the need for additional diagnostics and treatments of specific pediatric diseases or conditions, (3) the ethics, design, and analysis of clinical trials related to pediatric therapeutics (including drugs and biological products) and medical devices, (4) pediatric labeling disputes as specified in Public Law 107-109, Public Law 110-85, and Public Law 112-144, (5) pediatric labeling changes as specified in Public Law 107-109, Public Law 110-85, and Public Law 112-144, (6) adverse event reports for drugs studied under Public Law 107-109, 110-85 and labeled, and Public Law 112-144 (7) any safety issues that may occur as specified Public Law 107-109, Public Law 110-85, and Public Law 112-144, (8) any other pediatric issue or pediatric labeling dispute involving FDA-regulated products, (9) pediatric ethical issues including research involving children as subjects as specified in 21 CFR 50.54, (10) advise and make recommendations to the Secretary on the development of countermeasures for pediatric populations in H.R.307, Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and (11) any other matter involving pediatrics for which FDA has regulatory responsibility.
The Committee also advises and makes recommendations to the Secretary directly or to the Secretary through the Commissioner on research involving children as subjects that is conducted or supported by the Department of Health and Human Services as specified in 45 CFR 46.407.
Agency or Official to Whom the Committee Reports
The Committee provides advice to the Commissioner of Food and Drugs.
Support
Management and support services shall be provided by the Office of Commissioner
Estimated Annual Operating Costs and Staff Years
The estimated annual cost for operating the Committee, including compensation and travel expenses for members but excluding staff support, is $295,854. The estimated person years of staff support required is 4.6, at an estimated annual cost of $911,362.
Designated Federal Officer
FDA will select a fulltime or permanent part-time Federal employee to serve as the Designated Federal Officer (DFO) to attend each Committee meeting and ensure that all procedures are within applicable statutory, regulatory, and HHS General Administration Manual directives. The DFO will approve and prepare all meeting agendas, call all the Committee and subcommittee meetings, adjourn any meeting when the DFO determines adjournment to be in the public interest and chair meetings when directed to do so, by the official to whom the Committee reports. The DFO shall be present at all meetings of the full committee and subcommittees.
Estimated Number and Frequency of Meetings
Meetings shall be held approximately two to four times a year. Meetings shall be open to the public except as determined otherwise by the Commissioner or designee in accordance with the Government in the Sunshine Act (5 U.S.C. 552b(c)) and the Federal Advisory Committee Act. Notice of all meetings shall be given to the public.
Duration
Continuing
Termination
As provided in section 14(d) of the Best Pharmaceuticals for Children Act as amended by section 507 of the Food and Drug Administration Safety and Innovation Act of 2012, Pub. L. 112-144, notwithstanding section 14 of the Federal Advisory Committee Act, the Pediatric Advisory Committee will continue to operate to carry out the advisory committee's responsibilities under sections 505A, 505B, and 520(m) of the Federal Food, Drug, and Cosmetic Act.
Membership and Designation
The Committee shall consist of a core of 14 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of pediatric research, pediatric subspecialties, statistics, and/or biomedical ethics. Almost all non-Federal members of this committee serve as Special Government Employees. Federal members will serve as Regular Government Employees or Ex-Officios. The core of voting members may include one representative from a relevant patient or patient family organization and may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumer-oriented organizations or other interested persons. In addition to the voting members, the Committee may include two non-voting members who are identified with industry interests (drugs, biologics, vaccines and medical devices) and one non-voting member who represents a pediatric health organization.
The Commissioner or designee shall have the authority to select members of other scientific and technical FDA advisory committees (normally not to exceed 10 members) to serve temporarily as voting members and to designate consultants to serve temporarily as voting members when: (1) expertise is required that is not available among current voting standing members of the Committee (when additional voting members are added to the Committee to provide needed expertise, a quorum will be based on the combined total of regular and added members), or (2) to comprise a quorum when, because of unforeseen circumstances, a quorum is or will be lacking. Because of the size of the Committee and the variety in the types of issues that it will consider, FDA may, in connection with a particular committee meeting, specify a quorum that is less than a majority of the current voting members. The Agency's regulations (21 CFR §14.22(d)) authorize a committee charter to specify quorum requirements.
If functioning as a medical device panel, a non-voting representative of consumer interests and a non-voting representative of industry interests will be included in addition to the voting members.
Members shall be invited to serve for overlapping four-year terms.
Subcommittee
A permanent Pediatric Ethics Subcommittee of the Pediatric Advisory Committee will be established to advise and make recommendations to the Pediatric Advisory Committee on pediatric ethical issues, as well as IRB referrals related to clinical investigations involving children as subjects as specified in 21 CFR 50.54, and IRB referrals that involve both FDA regulated products under 21 CFR 50.54 and research involving children as subjects that is conducted or supported by the Department of Health and Human Services as specified in 45 CFR 46.407. The subcommittee will consist of two or more members of the parent Pediatric Advisory Committee and additional experts (e.g., science, medicine, education, ethics, and law) to address specific issues within their respective areas of expertise.
Temporary subcommittees consisting of two or more Committee members may be established by the Commissioner or designee as needed to address specific issues within their respective areas of expertise.
Subcommittees make preliminary recommendations regarding specific issues for subsequent action by the full Committee. The Department Committee Management Officer shall be notified upon establishment of each subcommittee, and shall be provided information on its name, membership, function, and estimated frequency of meetings.
Recordkeeping
Meetings of the Committee and its subcommittees will be conducted according to the Federal Advisory Committee Act, other applicable laws and Departmental policies. Committee and subcommittee records will be handled in accordance with General Records Schedule 6.2, Federal Advisory Committee Records or other approved agency records disposition schedule. These records will be available for public inspection and copying, subject to the Freedom of Information Act, 5 U.S.C. 552.
Filing Date
July 11, 2022
Approved:
Russell Fortney
Director, Advisory Committee Oversight and Management Staff